Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Heidelberg University.
Recruitment status was  Recruiting
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
First received: May 16, 2011
Last updated: May 19, 2011
Last verified: May 2011
Patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency might benefit from endoscopic implantation of intrabronchial valves.

Condition Intervention Phase
Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)
Device: Implantation of intrabronchial valves (IBV) (Spiration IBV)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

Resource links provided by NLM:

Further study details as provided by Heidelberg University:

Primary Outcome Measures:
  • Improvement in pulmonary function (FEV1 (forced expiratory volume in 1 second) and RV/TLC (residual volume/total lung capacity) [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of major complications [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Evaluation of IBV migration rate [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Average changes in pulmonary function (FEV1, VC (vital capacity), RV, TLC, RV/TLC) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Average changes in 6-minute-walk-distance [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: May 2011
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Implantation of intrabronchial valves (IBV) (Spiration IBV)
    In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of "new" air during inspiration.
    Other Name: Spiration IBV
Detailed Description:
Patient enrollment and data acquisition is to be carried out on a prospective basis. It is planned to enroll a total of 25 patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency. All patients will undergo treatment at one study centre in Heidelberg. Therapy of all patients consists of implantation of intrabronchial valves (IBV, Spiration, Olympus) in the most emphysematous destroyed lobe.

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • pulmonary function: FEV1 < 45 %, RV > 150 %, TLC > 100 %
  • alpha1 antitrypsin deficiency (< 80 mg/dl), genotype: PiZS, PiZZ, Pi0/0
  • heterogenous emphysema

Exclusion Criteria:

  • homogenous emphysema
  • significant bronchiectasis
  • severe concomitant diseases
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01357460

Contact: Daniela Gompelmann, MD +49(0)62213968087 daniela.gompelmann@thoraxklinik-heidelberg.de
Contact: Felix JF Herth, MD +49(0)62213961200 felix.herth@thoraxklinik-heidelberg.de

Thoraxklinik Recruiting
Heidelberg, Germany, 69126
Contact: Daniela Gompelmann, MD    +49(0)62213968087    daniela.gompelmann@thoraxklinik-heidelberg.de   
Principal Investigator: Daniela Gompelmann, MD         
Sponsors and Collaborators
Heidelberg University
Principal Investigator: Daniela Gompelmann, MD Heidelberg University
  More Information

Responsible Party: Thoraxklinnik Heidelberg, Thoraxklinik Heidelberg
ClinicalTrials.gov Identifier: NCT01357460     History of Changes
Other Study ID Numbers: Protocol D2.0 - 31.08.2010 
Study First Received: May 16, 2011
Last Updated: May 19, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Heidelberg University:
alpha1 antitrypsin deficiency
endoscopic lung volume reduction

Additional relevant MeSH terms:
Alpha 1-Antitrypsin Deficiency
Pulmonary Emphysema
Digestive System Diseases
Genetic Diseases, Inborn
Liver Diseases
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Subcutaneous Emphysema
Alpha 1-Antitrypsin
Protein C Inhibitor
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protease Inhibitors
Serine Proteinase Inhibitors
Trypsin Inhibitors

ClinicalTrials.gov processed this record on May 30, 2016